Extending our observations to the BEAT AML cohort (32), reporting the activity of elesclomol on 299 AML samples, we confirmed that SF3B1-mutated AMLs are significantly more sensitive to elesclomol than SF3B1 WT AMLs (Fig. 8B and fig. The gene discussed is SF3B1; the disease is acute myeloid leukemia.